Bioblast Pharma Ltd. is a clinical-stage, orphan disease-focused biotechnology company with a newly restructured management team, a promising platform technology, and a dynamic, emerging pipeline. Bioblast sought to communicate its renewed dedication to the rare disease community by clearly presenting the data to current and potential investors.
- Restore trust with all key stakeholders from investors to patients to physicians
- Introduce new management team with proven track record in orphan drug development
- Capture burden of disease and potential benefits to patients and their families
- Show clinical, commercial potential of the company’s platform technology across multiple diseases
- Build investor confidence in pipeline moving forward and help attract capital